[A further option in PI therapy. Approval of a new protease inhibitor in the USA].
D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019258:Saquinavir / Q000008:administration & dosage* / Q000009:adverse effects; D013608:Tablets, Enteric-Coated; D019562:Viral Load
D017320:HIV Protease Inhibitors; D013608:Tablets, Enteric-Coated; D019258:Saquinavir